Instructions Cerebrocurin solution for injection ampoule 2 ml No. 10
Composition
active ingredient: Cerebrocurin (active neuropeptides obtained from the brain of bovine embryos);
1 ml of solution contains 2 mg of Cerebrocurin;
excipients: sodium chloride, water for injection, quinozole.
Dosage form
Solution for injection.
Main physicochemical properties: clear liquid from light yellow to light brown.
Pharmacotherapeutic group
Psychostimulants and nootropics. ATX code N06B X.
Pharmacological properties
Pharmacodynamics.
The peptide modulator Cerebrocurin® affects higher nervous activity by activating the energy-producing and protein-synthesizing function of nerve cells and increasing the activity of the synaptic apparatus of neurons.
Cerebrocurin® promotes an increase in the diameter of mitochondria, an increase in their area per unit volume and the restoration of myelin sheaths in brain neurocytes, the mosaic destruction of which occurs during hypoxic damage to neurocytes. The drug has a nootropic and vasoactive effect, and has a regulatory effect on the bioelectric activity of the brain.
Cerebrocurin® improves arterial and venous cerebral blood circulation. Nootropic, hypolipidemic, hepatoprotective, anabolic action promotes the restitution of impaired functions of the central nervous system caused by both functional and organic brain damage, normalizes emotional and memory functions, expands the range of adaptive reactions, which contributes to the physical, mental and social rehabilitation of patients with nervous and mental diseases.
In hereditary and genetically determined diseases, Cerebrocurin® has a stabilizing nootropic effect.
Pharmacokinetics.
Studying pharmacokinetics is impossible because the active neuropeptides that make up the drug are present in the body in the form of high-molecular-weight precursor proteins, the biosynthesis of which occurs in the postnatal period.
Indication
Diseases characterized by dysfunction of the central nervous system, in particular various forms of neurocirculatory dystonia, chronic ischemic dyscirculatory and post-traumatic encephalopathies, residual effects of acute cerebrovascular accident.
As an adjuvant - after neurosurgical reconstructive operations on the main vessels of the head; in Alzheimer's disease, Binswanger syndrome (ischemic periventricular ariolis), in chronic fatigue syndrome and age-related dementia of vascular genesis, mixed forms of dementia, intellectual dynamic disorders, psychoorganic syndrome with intellectual disability; consequences of encephalitis; Down's disease, Rett and Martin-Bell syndromes.
In ophthalmological practice – senile macular degeneration (dry and wet forms), high complicated myopia, conditions after retinal detachment, partial atrophy of the optic nerve, post-traumatic macular degeneration, central serous chorioretinopathy, non-proliferative diabetic retinopathy without pronounced macular edema, glaucoma with compensated intraocular pressure.
In pediatric practice - with delayed mental development and speech, congenital alalia and dyslexia, consequences of stroke with aphasia, cerebral palsy with psychospeech delay (mild), apalic (decortication) syndrome - in the subacute period and its consequences without frequent epileptic seizures, consequences of encephalitis or craniocerebral trauma with disorders of intellectual functions and persistent cephalalgias, flaccid paralysis. In the neonatal period - with moderate and severe asphyxia, consequences of severe chronic hypoxia.
Contraindication
Increased individual sensitivity to the components of the drug, pregnancy, breastfeeding.
Interaction with other medicinal products and other types of interactions
No interaction was observed.
Application features
Prescribe with caution in cases of allergy. Patients with status epilepticus and seizures should use Cerebrocurin® under medical supervision.
Children are not recommended to use Cerebrocurin® at night.
During treatment with the drug, you should not drink alcohol.
Use during pregnancy or breastfeeding
Cerebrocurin® is not recommended for use by women during pregnancy or breastfeeding.
The ability to influence the speed of reactions when driving vehicles or other mechanisms
Does not affect the ability to drive vehicles and work with other mechanisms.
Method of administration and doses
Cerebrocurin® should be administered intramuscularly.
In pediatric practice, use from the first days of life to 6 months of age - 0.5 ml every other day, a course of treatment - 3-5 injections; from 6 months to 1 year of age - 0.5 ml every other day, a course of treatment - 10 injections; for children aged 1-3 years - 1-2 ml every other day, a course of treatment - 10 injections; from 3 years of age - 2 ml every other day, 10-20 injections. It is advisable to repeat courses (2-4) after 1-3 months.
Newborns and children under 3 years of age should be treated with the drug in a hospital setting.
In ophthalmological practice, Cerebrocurin® is administered intramuscularly: 2 ml daily or the first five injections intramuscularly, then 1 ml peribulbarly, 1 ml intramuscularly. Injections should be performed daily, without interruption. The minimum course of treatment is 10 injections.
Children
In pediatric practice, use from the first days of life.
Overdose
No cases of drug overdose have been observed.
Side effects
Individual sensitivity to the components of the drug is possible. When using the drug in the treatment of cerebral palsy with symptomatic epilepsy, such side effects as increased frequency of seizures, headache, and excessive excitability can be expected.
Expiration date
2 years.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store in the original packaging, at a temperature of +2 °C to +8 °C, out of the reach of children. Do not freeze!
Packaging
0.5 ml in an ampoule, 5 ampoules in a cardboard box with a polymer cell insert.
2 ml in an ampoule, 5 or 10 ampoules in a cardboard box with a polymer cell insert.
Vacation category
According to the recipe.
Producer
LLC "NIR".
Location of the manufacturer and its business address
Ukraine, 02155, Kyiv, Kharkiv highway, 50.
